Ocular Therapeutix, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 267
- Market Cap
- -
- Website
- http://www.ocutx.com
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Ocular Therapeutix, Inc.
- Target Recruit Count
- 153
- Registration Number
- NCT04362670
- Locations
- 🇺🇸
Ocular Therapeutix, Inc., Murray, Utah, United States
🇺🇸Ocular Therapeutix, Inc, Saint Louis, Missouri, United States
🇺🇸Ocular Therapeutix, Lakeway, Texas, United States
CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension
Phase 1
Completed
- Conditions
- Open Angle GlaucomaOcular Hypertension
- Interventions
- Drug: OTX-TIC
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Ocular Therapeutix, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT04360174
- Locations
- 🇺🇸
Ocular Therapeutix, Inc., Racine, Wisconsin, United States
🇺🇸Ocular Therapeutix, Inc, Roswell, Georgia, United States
A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert
Phase 3
Completed
- Conditions
- Open Angle Glaucoma and Ocular Hypertension
- Interventions
- Drug: Ophthalmic Insert
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Ocular Therapeutix, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04061044
- Locations
- 🇺🇸
ApexEye, Cincinnati, Ohio, United States
A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis
Phase 3
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- Drug: Dexamethasone, 0.4mgDevice: Placebo plug with no drug
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2021-10-07
- Lead Sponsor
- Ocular Therapeutix, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT04050865
- Locations
- 🇺🇸
Vision Institute, Colorado Springs, Colorado, United States
🇺🇸The Eye Care Institute, Louisville, Kentucky, United States
🇺🇸Andover Eye Associates, Raynham, Massachusetts, United States
CLN-0046: Treatment of AMD Subjects With OTX-TKI
Phase 1
Completed
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Drug: Anti-VEGF
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Ocular Therapeutix, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT03630315
- Locations
- 🇦🇺
Ocular Therapeutix, Inc., Melbourne, Australia
🇦🇺Ocular Therapeutiux, Inc., Sydney, Site 3, Australia
OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
Phase 3
Completed
- Conditions
- Chronic Allergic Conjunctivitis
- Interventions
- Other: Placebo Vehicle
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Ocular Therapeutix, Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT02988882
Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
Phase 3
Completed
- Conditions
- Open Angle GlaucomaOcular Hypertension
- Interventions
- Other: Placebo Vehicle
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Ocular Therapeutix, Inc.
- Target Recruit Count
- 565
- Registration Number
- NCT02914509
OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
Phase 3
Completed
- Conditions
- Post-Surgical Ocular PainPost-Surgical Ocular Inflammation
- Interventions
- Other: Placebo Vehicle
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- Ocular Therapeutix, Inc.
- Target Recruit Count
- 438
- Registration Number
- NCT02736175
OTX-14-006: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Dry Eye
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Ocular Therapeutix, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02468700
OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
Phase 3
Completed
- Conditions
- Chronic Allergic Conjunctivitis
- Interventions
- Other: Placebo Vehicle
- First Posted Date
- 2015-05-15
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Ocular Therapeutix, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT02445326